Completed PHASE2 INTERVENTIONAL 8-arm NCT05966272

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

A Multi-center, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions Type 2 Diabetes

Interventions HRS9531 injection HRS9531 injection Placebo

Updated 7 times since 2023 Last updated: May 5, 2025 Started: Aug 12, 2023 Primary completion: Sep 24, 2024 Completion: Sep 24, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by Fujian Shengdi Pharmaceutical Co., Ltd. and has accumulated 7 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE2
May 2025 — Jun 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — May 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Sep 2023 — Jan 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Shengdi Pharmaceutical Co., Ltd.

Data source: Fujian Shengdi Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China